NYSE · WAT
Healthcare · Medical - Diagnostics & Research
$414.69
Down-$6.57 (-1.56%)
Updated Aug 31, 2026, 8:22 AM
SID Score
5.9/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
WAT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning WAT.
WAT research
Company profile and research snapshot.
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2026 | Piper Sandler | Overweight | — |
| Aug 10, 2026 | Citigroup | Buy | — |
| Aug 5, 2026 | Wells Fargo | Equal-Weight | — |
| Aug 5, 2026 | Evercore ISI Group | Outperform | — |
| Aug 5, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
Yahoo · Feb 27, 2026
After losing some value lately, a hammer chart pattern has been formed for Waters (WAT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Yahoo · Feb 25, 2026
Waters Corporation (NYSE:WAT) plans to merge with BD's life science and diagnostics business, targeting completion in early 2026. The transaction is expected to shift Waters' business mix toward diagnostics and life science tools. Shareholders are watching for how this combination could influence future revenue sources and competitive position. Waters, trading at around $326.3 per share, is approaching this planned merger after a period of mixed share performance. The stock is up 1.5% over...
Yahoo · Feb 24, 2026
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. US equities […]
Yahoo · Feb 23, 2026
Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the TD Cowen Health Care Conference on Monday, March 2nd, 2026, at 11:10 AM Eastern Time.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning WAT.
